This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars

This study has been completed.
Information provided by (Responsible Party):
Galderma Identifier:
First received: September 30, 2010
Last updated: March 9, 2015
Last verified: March 2015
The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.

Condition Intervention Phase
Acne Scars Drug: Adapalene Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars. A Pilot Study.

Resource links provided by NLM:

Further study details as provided by Galderma:

Primary Outcome Measures:
  • Global Scarring Severity [ Time Frame: Week 24 ]

    Grade Level:

    1. Macular disease
    2. Mild disease
    3. Moderate disease
    4. Severe disease

Enrollment: 20
Study Start Date: March 2011
Study Completion Date: September 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Differin 0.3%

Differin® 0.3% Gel

Adapalene 0.3%

Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks.

Drug: Adapalene
Adapalene Gel 0.3%
Other Name: Differin 0.3%


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects of any race, aged 18 to 50 years inclusive
  • Subjects with a past history of acne and with moderate to severe facial atrophic acne scars

Exclusion Criteria:

  • Subjects with active inflammatory acne lesions
  • Subjects with hypertrophic acne scars
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01213199

United States, Maryland
Manisha PATEL
Baltimore, Maryland, United States, 21231
Sponsors and Collaborators
Principal Investigator: Manisha J. Patel, MD Johns Hopkins Medical Institut
  More Information

Additional Information:
Responsible Party: Galderma Identifier: NCT01213199     History of Changes
Other Study ID Numbers: RD.03.SPR.29088
Study First Received: September 30, 2010
Results First Received: November 22, 2013
Last Updated: March 9, 2015

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Dermatologic Agents processed this record on August 21, 2017